Oncology · Small MoleculeTrial Updateclinicalmid-term

Phase I/II Study of LBL-024 in Advanced Malignant Tumors Initiated by Nanjing Leads Biolabs

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/2/2026, 12:31:03 AM

Assessment confidence: 72% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The initiation of the Phase I/II trial for LBL-024 by Nanjing Leads Biolabs is significant as it may address unmet needs in advanced malignancies, potentially reshaping treatment paradigms in oncology. Pharma strategy teams should closely monitor this trial to evaluate its implications for competitive positioning and market dynamics. Regulatory context from FDA (Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease) supports the near-term read.

Strategic Assessment

Portfolio teams should assess LBL-024's potential impact on treatment paradigms and competitive positioning in oncology. The strongest clinical anchor is A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors (ClinicalTrials.gov), entity match (lbl-024); patient population match (advanced). In Oncology · Small Molecule, 3 regulatory and 6 competitive items passed relevance filtering for LBL-024.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sponsor/company relevance (pfizer); patient population match (advanced). Secondary pressure from Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC).

Regulatory Outlook

Regulatory risk is concentrated around Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease (FDA). Patient population match (advanced). The trial's outcomes will influence future regulatory submissions and potential approvals, particularly if LBL-024 demonstrates significant efficacy.

Key Risks

Elevated medium regulatory exposure for LBL-024 could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If successful, LBL-024 could capture market share in a competitive oncology landscape, impacting revenue streams for existing therapies.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial evaluating combination regimens for the first-line treatment of patients with advanced clear cell renal cell carcinoma (RCC).
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.
Upside for LBL-024 may improve if A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as Single Agent and in Combination in Patients With Advanced Solid Tumors (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial progress, patient enrollment rates, and preliminary efficacy data from the Phase I/II study.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Hepatitis C Medicines (Mavyret, Zepatier, and Vosevi): Drug Safety Communication - Due to Rare Occurrence of Serious Liver Injury in Some patients with Advanced Liver Disease
FDAhigh relevance
Patient population match (advanced)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
ClinicalTrials.govhigh relevance
Entity match (lbl-024); Patient population match (advanced)
FDA document
View source
A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as Single Agent and in Combination in Patients With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
ClinicalTrials.govhigh relevance
Patient population match (advanced)
FDA document
View source
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
ClinicalTrials.govmedium relevance
Patient population match (advanced)
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sponsor/company relevance (Pfizer); Patient population match (advanced)
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckhigh relevance
Sponsor/company relevance (Merck); Patient population match (advanced)
FDA document
View source
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merckhigh relevance
Sponsor/company relevance (Merck)
FDA document
View source
Cabozantinib plus Nivolumab Shows Promise in Advanced Non-Clear Cell RCC
Humanexa Signalshigh relevance
Patient population match (advanced)
Roche's ENSPRYNG shows 68% relapse reduction in Phase III MOGAD study
Humanexa Signalsmedium relevance
Sponsor/company relevance (Roche)
Phase 3 Trial of Navenibart for Hereditary Angioedema Initiated by Astria Therapeutics
Humanexa Signalsmedium relevance
Moderate corpus alignment

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedhigh relevance
Patient population match (advanced)
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Exploiting the dynamics of hyperthermia-enhanced delivery of thermosensitive liposomal doxorubicin to solid tumors.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
The role of capacitive hyperthermia as an adjunct treatment in oncology: a systematic review of randomized phase III trials.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

LBL-024

Commercial impact

medium

If successful, LBL-024 could capture market share in a competitive oncology landscape, impacting revenue streams for existing therapies.

Regulatory impact

medium

The trial's outcomes will influence future regulatory submissions and potential approvals, particularly if LBL-024 demonstrates significant efficacy.

What to watch

Monitor trial progress, patient enrollment rates, and preliminary efficacy data from the Phase I/II study.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.